Vanguard Group Inc Petros Pharmaceuticals, Inc. Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.47 - $5.1 $64,283 - $697,542	136,773 Added 114.8%	255,914 $131,000
Q2 2022 Aug 12, 2022	BUY	$0.68 - $1.49 $3,616 - $7,923	5,318 Added 4.67%	119,141 $100,000
Q1 2022 May 13, 2022	SELL	$1.07 - $3.36 $40,043 - $125,744	-37,424 Reduced 24.74%	113,823 $178,000
Q4 2021 Feb 14, 2022	BUY	$1.33 - $4.09 $55,240 - $169,874	41,534 Added 37.86%	151,247 $504,000
Q3 2021 Nov 12, 2021	BUY	$1.82 - $3.2 $4,027 - $7,081	2,213 Added 2.06%	109,713 $219,000
Q2 2021 Aug 13, 2021	BUY	$2.87 - $4.11 $308,525 - $441,825	107,500 New	107,500 $336,000

Ticker PTPI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 20,708,000
Market Cap $5.18M
Description
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for th...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.